Key Decisions in HIV Care: PrEP Considerations in Cisgender Women

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender women, including:

• Discussion of the PrEP gap and racial and gender disparities in PrEP access
• CDC, EACS, and WHO guidance on PrEP eligibility
• PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir
• Data from phase III trials on the efficacy of FTC/TDF daily for women including Partners PrEP, TDF, VOICE, and FEM-PrEP
• Pharmacokinetic data of FTC/TDF and FTC/TAF in the female genital tract and discussion of why on-demand dosing of FTC/TDF is not recommended in cisgender women
• Data and recommendations for the use of the dapivirine ring from ASPIRE and The Ring Study and their open-label extensions, DREAM and HOPE
• Data from the HPTN084 study on the use of long-acting cabotegravir as PrEP for cisgender women
• Recommendations for the use of PrEP during pregnancy and breastfeeding
• Clinical monitoring and considerations during PrEP use

Presenters:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama

Karine Lacombe, MD, PhD
Professor
UMR-S1136
Sorbonne University
Head, Infectious Diseases Department
St Antoine Hospital, AP-HP
Paris, France

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at:
https://bit.ly/36s2ovB

Link to full program:
https://bit.ly/3q2DlGd

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.